logo
Why BlackBerry Stock Soared This Week

Why BlackBerry Stock Soared This Week

Yahooa day ago

BlackBerry reported its latest earnings this week, beating Wall Street targets.
The company's automotive software showed strong growth, and its secure communications segment continues to deliver.
10 stocks we like better than BlackBerry ›
Shares of BlackBerry (NYSE: BB) jumped this week, up 9% as of 1:22 p.m. ET on Friday. The rise comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq-100 gained 3.6% and 4.4%, respectively.
The company, which has reinvented itself as a software provider, released its Q1 2026 (ended May 31) financial results, beating consensus estimates for most metrics and setting rosy guidance.
BlackBerry reported better-than-expected Q1 2026 results earlier this week. The company's first-quarter earnings per share (EPS) came in at $0.02, $0.02 over consensus estimates. While revenue declined 1.4% year over year (YOY), the $121.7 million in sales still topped estimates.
BlackBerry's QNX automotive software -- a sort of operating system for cars -- is seeing stronger-than-expected growth, up 4% YOY to $57.5 million. On the strength of its QNX sales and growth in its secure communications segment, the company raised its overall 2026 revenue forecast to between $508 million and $538 million.
In a statement, CEO Brian John J. Giamatteo said of the quarter, "Both our QNX and Secure Communications divisions continue to execute effectively against their strategies, beating both top line and profitability expectations."
In the years since the company's "crackberries" dominated the smartphone market, the company has worked to reinvent itself, ditching device-making for software. Things look to be paying off as the company shrinks its net loss and approaches profitability. Still, there's a decent amount of hype built in, and its stock is too expensive at the moment for my taste.
Before you buy stock in BlackBerry, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and BlackBerry wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!*
Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends BlackBerry. The Motley Fool has a disclosure policy.
Why BlackBerry Stock Soared This Week was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Citi Maintains ‘Neutral' Rating on EchoStar Corporation (SATS); Raises PT
Citi Maintains ‘Neutral' Rating on EchoStar Corporation (SATS); Raises PT

Yahoo

time10 minutes ago

  • Yahoo

Citi Maintains ‘Neutral' Rating on EchoStar Corporation (SATS); Raises PT

EchoStar Corporation (NASDAQ:SATS) is one of the best stocks for a . The corporate headquarters of a satellite radio systems company, illuminating the skyline. As announced on June 24, 2025, Citi maintained a 'Neutral' rating on EchoStar Corporation (NASDAQ:SATS), raising its price target from $27 to $28.50. The analyst cited its reevaluation of EchoStar's potential value related to its spectrum assets. These assets include the company's licenses for radio frequencies used for communication. Furthermore, Citi expects a strategic update to be announced by the company within 30 days. The analyst highlights its importance as this expected development would come at a critical time, as EchoStar approaches a bond-related interest payment milestone. EchoStar Corporation (NASDAQ:SATS), a U.S.-based telecommunications company, delivers broadband, wireless, and satellite services through its Pay-TV, Retail Wireless, and BSS segments, and is also part of our growth stock portfolio. While we acknowledge the potential of SATS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 10 Overlooked Tech Stocks to Buy Now and 10 Low Risk High Reward Stocks Set to Triple by 2030. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BMO Capital Maintains ‘Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT
BMO Capital Maintains ‘Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT

Yahoo

time10 minutes ago

  • Yahoo

BMO Capital Maintains ‘Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best stocks added in a . A well-stocked pharmacy shelf full of the company's pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products. BMO Capital maintained an 'Outperform' rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), announcing this on June 24, 2025. The analyst raised its price target on the company's stock from $300 to $360. BMO Capital attributed this update to a drastic increase in Amvuttra sales for ATTR-CM, according to IQVIA tracking data, after the drug's approval in March. Furthermore, the analyst cited the continued consistency of the company's sales trends, reinforcing confidence in its commercial traction. While short-term skepticism exists regarding the company's revenue growth, Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) consistent historical trend of revenue and pipeline growth supports its potential for continued growth. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a biopharmaceutical company, develops and markets RNAi therapeutics for rare and genetic diseases. The company has demonstrated consistent YoY revenue growth, making it part of the growth stock portfolio. While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 10 Best Marketing Stocks to Buy Right Now and 10 Best Cybersecurity Stocks to Invest in Under $20. Disclosure: None.

Key Senators Strike Deal To Pause State AI Laws For Five Years
Key Senators Strike Deal To Pause State AI Laws For Five Years

Bloomberg

time19 minutes ago

  • Bloomberg

Key Senators Strike Deal To Pause State AI Laws For Five Years

The Senate is poised to approve a controversial provision preventing some US states from regulating artificial intelligence, marking a victory for the tech companies, venture capital firms and startups that backed it. The language, which is part of President Donald Trump's signature tax legislation, had drawn opposition from a handful of Republican senators who derided the provision as a giveaway to the biggest tech companies.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store